TrialThe Lancet. Haematology2022

Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.

Gina L Mazza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.